lopinavir/ritonavir / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 77 Diseases   69 Trials   69 Trials   4434 News 


«12...2627282930313233343536...4546»
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, lopinavir/ritonavir / Generic mfg.
    Journal:  Potential specific therapies in COVID-19. (Pubmed Central) -  May 26, 2020   
    The use of corticosteroids should be avoided in COVID-19 pneumonia unless used for other indications, based on the suggestion of harm in patients with SARS-COV-1 and Middle Eastern Respiratory Syndrome (MERS) infection. The reviews of this paper are available via the supplemental material section.
  • ||||||||||  chloroquine phosphate / Generic mfg., lopinavir/ritonavir / Generic mfg.
    Journal:  Chloroquine as a possible treatment for COVID-19 (Pubmed Central) -  May 23, 2020   
    Recently, the Dutch National Institute for Public Health and the Environment published treatment options for antiviral treatment for COVID-19 where chloroquine was suggested as first choice for off-label treatment, beside remdesivir en lopinavir/ritonavir. In this commentary, we provide a background and history of chloroquine, the evidence for antiviral efficacy of chloroquine and the arguments for off-label use of chloroquine in COVID-19.
  • ||||||||||  hydroxychloroquine / Generic mfg., lopinavir/ritonavir / Generic mfg.
    Enrollment change, Trial termination:  Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19) (clinicaltrials.gov) -  May 22, 2020   
    P2,  N=65, Terminated, 
    In this commentary, we provide a background and history of chloroquine, the evidence for antiviral efficacy of chloroquine and the arguments for off-label use of chloroquine in COVID-19. N=150 --> 65 | Recruiting --> Terminated; Terminated early because no patients were further enrolled since mid-Apr 2020.
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Clinical, Review, Journal:  COVID-19 in Children: Clinical Approach and Management. (Pubmed Central) -  May 21, 2020   
    To prevent post discharge dissemination of infection, home isolation for 1-2 wk may be advised. As of now, no vaccine or specific chemotherapeutic agents are approved for children.
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Clinical, Journal:  COVID-19: An Update About the Discovery Clinical Trial. (Pubmed Central) -  May 20, 2020   
    Whereas plasma therapy attracts much interest, the European project Discovery focuses on the potentialities of small molecules like remdesivir, the combination of lopinavir/ritonavir, hydroxychloroquine, and chloroquine. Results recently published on the clinical evaluation of those drugs are compiled in this brief report, although complete data are still impatiently awaited.
  • ||||||||||  Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  MERS-CoV Infection tReated With A Combination of Lopinavir /Ritonavir and Interferon Beta-1b (clinicaltrials.gov) -  May 20, 2020   
    P2/3,  N=95, Completed, 
    Results recently published on the clinical evaluation of those drugs are compiled in this brief report, although complete data are still impatiently awaited. Recruiting --> Completed | N=194 --> 95 | Trial completion date: Dec 2020 --> May 2020 | Trial primary completion date: Dec 2020 --> May 2020
  • ||||||||||  Trial initiation date:  Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia (clinicaltrials.gov) -  May 19, 2020   
    P=N/A,  N=426, Not yet recruiting, 
    Recruiting --> Completed | N=194 --> 95 | Trial completion date: Dec 2020 --> May 2020 | Trial primary completion date: Dec 2020 --> May 2020 Initiation date: Feb 2020 --> May 2020
  • ||||||||||  lamivudine / Generic mfg., lopinavir/ritonavir / Generic mfg.
    Journal:  Antiretroviral drug-induced endothelial dysfunction is improved by dual PPARα/γ stimulation in obesity. (Pubmed Central) -  May 19, 2020   
    Improved endothelial function in obese+ HAART+Saroglitazar group was associated with upregulation of eNOS, PKB/Akt and downregulated p22-phox expression vs. obese+HAART group. Therefore, PPARα/γ stimulation attenuated HAART-induced endothelial dysfunction by upregulating vasoprotective eNOS, PKB/Akt signaling and downregulating pro-oxidative p22-phox expression.
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Journal:  Management of COVID-19: the Zhejiang experience (Pubmed Central) -  May 16, 2020   
    Early antiviral treatment could alleviate disease severity and prevent illness progression, and we found lopinavir/ritonavir combined with abidol showed antiviral effects in COVID-19...Therefore, two weeks' quarantine for discharged patients was required and a regular following up was also needed.The Zhejiang experience and suggestions have been implemented in our center and achieved good results. However, since COVID-19 was a newly emerging disease, more work was warranted to improve strategies of prevention, diagnosis and treatment for COVID-19.
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Clinical, Journal:  Report of 5 nurses infecting COVID-19 during patient care: case Series. (Pubmed Central) -  May 16, 2020   
    This study showed that regardless of self caring, the nurses were exposed to COVID-19. Because at the the beginning of SARS-CoV-2 outbreak in Iran, there were no special protection against this infection.Therfore they were at risk for the COVID-19.This study also reported that receiving the necessary care and treatment at home was a good experience for nurses that can be used in some cases.
  • ||||||||||  favipiravir / Generic mfg., lopinavir/ritonavir / Generic mfg.
    Clinical, Journal:  A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic? (Pubmed Central) -  May 16, 2020   
    Favipiravir may be safe and tolerable in short-term use, but more evidence is needed to assess the longer-term effects of treatment. Given the limitations of the evidence and unresolved safety concerns, caution is warranted in the widespread use of favipiravir against pandemic COVID-19.
  • ||||||||||  Daklinza (daclatasvir) / BMS, lopinavir/ritonavir / Generic mfg.
    Journal:  Minimum costs to manufacture new treatments for COVID-19. (Pubmed Central) -  May 16, 2020   
    Should repurposed drugs demonstrate efficacy against COVID-19, they could be manufactured profitably at very low costs, for much less than current list prices. Estimations for the minimum production costs can strengthen price negotiations and help ensure affordable access to vital treatment for COVID-19 at low prices globally.
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Journal:  Antivirals for COVID-19. (Pubmed Central) -  May 16, 2020   
    Antivirals to treat influenza (oseltamivir) have limited activity against SARS-CoV-2, but favipiravir and umifenovir, influenza antivirals available internationally, have distinct viral targets and require further investigation. Antivirals with evidence of clinical activity must be studied as treatment and prophylaxis for those at high risk for severe COVID-19.
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Clinical, Journal:  A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. (Pubmed Central) -  May 13, 2020   
    Future trials in patients with severe illness may help to confirm or exclude the possibility of a treatment benefit. (Funded by Major Projects of National Science and Technology on New Drug Creation and Development and others; Chinese Clinical Trial Register number, ChiCTR2000029308.).
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Clinical, Journal:  Outbreak of COVID-19 infection in children: fear and serenity. (Pubmed Central) -  May 13, 2020   
    No sufficient results have been reached by the use of interferon (IFN), lopinavir/ritonavir, orbidol, and oseltamivir in the treatment of the coronaviruses infection. The aim of this short review is to highlight the differences existing between COVID-19 cases in adults and children.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, lopinavir/ritonavir / Generic mfg.
    Review, Journal:  Options for controlling new Corona virus infection - 2019-nCoV (Pubmed Central) -  May 10, 2020   
    In the system operation it is necessary to create the socalled a safety matrix that would take into account the existing threat on the one hand and all available services and resources on the other. Precise analysis and separation of individual tasks can enable the creation of a real crisis management plan.
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Clinical, Clinical guideline, Review, Journal:  Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines. (Pubmed Central) -  May 8, 2020   
    While many of these adjunctive drugs are being investigated in clinical trials, professional bodies have attempted to clarify the setting where the use of these drugs may be considered as off-label or compassionate use. This review summarizes the clinical evidence of investigational adjunctive treatments used in COVID-19 patients as well as the recommendations of their use from guidelines issued by international and national organizations in healthcare.
  • ||||||||||  ritonavir / Generic mfg., lopinavir/ritonavir / Generic mfg.
    Journal:  Binding site analysis of potential protease inhibitors of COVID-19 using AutoDock. (Pubmed Central) -  May 5, 2020   
    From the output of multiple sequence alignment, it is evident that ligand binding sites were conserved. The current in silico study thus, provides structural insights about the protease of COVID-19 and also its molecular interactions with some of the known protease inhibitors.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, ibuprofen / Generic mfg., lopinavir/ritonavir / Generic mfg.
    Journal:  Some drugs for COVID-19. (Pubmed Central) -  Apr 30, 2020   
    This article attempted to summarize available information on the reported anti-viral activity of some natural products. No abstract available